Lumito

The SAB, where a few have had direct previous experience with nanoparticles, concluded that Lumitos nanoparticle technology has solved most of the issues experienced in the past. Lumitos nanoparticles demonstrate physical properties and characteristics that make the technology reliable and effective. In addition, the SAB concluded that the absence of disturbing autofluorescence from the tissue itself is a significant advantage in preclinical and clinical applications.

An area that was also discussed and highlighted in SAB was the potential of Lumito’s solution, due to its high accuracy and no autofluorescence from the tissue, to provide cleaner data sets. This can lead to better training of AI algorithms, improving biomarker development and ultimately ensuring that the right patients receive the right treatment.

“Having the opportunity to get in-depth discussions with these experts, and to get their honest view on our technology, solution, and overall business was extremely valuable. The board’s affirmation of our product is an important step in our commercial journey,” comments Sanna Wallenborg, CEO at Lumito.